Ductal Carcinoma in Situ (DCIS) Program

The Dana-Farber Brigham Cancer Center team of breast cancer experts is dedicated to improving clinical care and advancing research for patients with ductal carcinoma in situ (DCIS). Our physician-scientists are engaged in multiple research studies to better understand the risk of progression to invasive disease, and to better tailor treatment options to meet the needs of patients with DCIS.

Patients at Dana-Farber Brigham Cancer Center have access to leading-edge research and the opportunity to join clinical trials. Your team will discuss whether a clinical trial may be right for you. Together, we will advance the understanding of DCIS in order to provide more personalized treatment and prevention strategies for patients now and in the future.

Featured Clinical Trials

Trial 18-075: A large-scale multicenter phase II study evaluating the protective effect of a tissue selective estrogen complex (TSEC) in women with newly-diagnosed ductal carcinoma in situ
Principal Investigator: Judy E. Garber, MD, MPH

This study looks at the potential role of the medication DUAVEE in preventing DCIS from developing into an invasive cancer. Patients opting into the study will be asked to take a medication for approximately one month prior to surgery. The research team will collect breast tissue from your biopsy and your surgical specimen to look for changes in the DCIS cells.

Trial 17-131: Comparison of operative to monitoring and endocrine therapy (COMET) trial for low-risk DCIS: A phase III prospective randomized trial
Principal Investigator: Anna Weiss, MD

This study examines the likelihood of progression from DCIS to invasive breast cancer in women with low-risk DCIS who undergo either watchful waiting (no surgery) or standard care (surgery).